Exabis Library
Welcome to the e-CCO Library!
OP21: COVID-19 morbidity/mortality and vaccination against SARS-CoV-2 in patients with Inflammatory Bowel Disease in Poland: Nationwide Data
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 10:43 AM
OP21: COVID-19 vaccine-induced antibody responses are impaired in Inflammatory Bowel Disease patients treated with infliximab, ustekinumab or tofacitinib, but not thiopurines or vedolizumab
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
OP21: Predictive value of Milan Ultrasound Criteria in Ulcerative Colitis: A prospective observational cohort study
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
OP22 Crohn’s disease exclusion diet reduces bacterial dysbiosis towards healthy controls in paediatric Crohn’s disease
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
OP22: Antibody decay, T cell immunity and breakthrough infections following SARS-CoV-2 vaccination in infliximab- and vedolizumab-treated patients
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
OP22: Factors independently associated with fatigue in IBD: Results from the baseline dataset of the PREdiCCt study
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
OP22: Mesenchymal stromal cell-derived exosomes stimulate epithelial regeneration in vitro and reduce experimental colitis
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
OP22: The risk of cancer in pediatric-onset immune-mediated inflammatory diseases – a nationwide Danish study from 1980-2018.
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 10:43 AM
OP23 Efficacy and safety of vedolizumab SC in patients with moderately to severely active Crohn’s disease: Results of the VISIBLE 2 study
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
OP23: Asymptomatic inflammatory bowel disease diagnosed during the colorectal cancer population screening in Catalonia
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 10:43 AM
OP23: CKD-506, a novel histone deacetylase (HDAC) 6 inhibitor, ameliorates colitis in various animal models
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
OP23: Efficacy and safety of upadacitinib as induction therapy in patients with Moderately to Severely Active Ulcerative Colitis: Results from phase 3 U-ACCOMPLISH study
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
OP23: The efficacy and safety of guselkumab induction therapy in patients with moderately to severely active Ulcerative Colitis: Phase 2b QUASAR Study results through week 12
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
OP24 A novel subcutaneous infliximab (CT-P13): 1-year results including switching results from intravenous infliximab (CT-P13) in patients with active Crohn’s disease and ulcerative colitis
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
OP24: Clinical efficacy and safety of guselkumab maintenance therapy in patients with moderately to severely active Crohn’s Disease: Week 48 analyses from the phase 2 GALAXI 1 study
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
OP24: Effectiveness and safety of ustekinumab 90 mg every 4 weeks in Crohn’s disease
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
OP24: Efficacy and safety of upadacitinib induction therapy in patients with Moderately to Severely Active Ulcerative Colitis: Results from the phase 3 U-ACHIEVE study
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
OP24: Neutralising antibody potency against SARS-CoV-2 wild-type and Omicron BA.1 and BA.4/5 variants in infliximab and vedolizumab treated patients with Inflammatory Bowel Disease after three doses of COVID-19 vaccine: a prospective multicentre cohort study
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 10:43 AM
OP25 Biologics before surgery for IBD: Are they associated with post-operative infectious outcomes? Results from the national surgical quality improvement programme inflammatory bowel disease collaborative
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
OP25: Efficacy of filgotinib in patients with Ulcerative Colitis by line of therapy in the phase 2b/3 SELECTION trial
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM